Towards compatibility of EUnetHTA JCA methodology and German HTA: a systematic comparison and recommendations from an industry perspective

被引:0
作者
Agnes Kisser
Joschua Knieriemen
Annette Fasan
Karolin Eberle
Sara Hogger
Sebastian Werner
Tina Taube
Andrej Rasch
机构
[1] Pfizer Pharma GmbH,
[2] AbbVie Deutschland GmbH & Co. KG,undefined
[3] AMS Advanced Medical Services GmbH,undefined
[4] Verband Forschender Arzneimittelhersteller e.V.,undefined
来源
The European Journal of Health Economics | 2022年 / 23卷
关键词
Act on the Reform of the Market for Medicinal Products (AMNOG); EUnetHTA; Relative effectiveness assessment; Health technology assessment; I10; I18;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:863 / 878
页数:15
相关论文
共 74 条
[11]  
Vitre P(2019)A comparison of national guidelines for network meta-analysis Value Health. 22 1178-S410
[12]  
Osinska B(2019)HT2 Is there potential for joint health technology assessment (HTA) in Europe? An evaluation of EUnetHTA joint clinical assessments vs. national appraisals in oncology Value in Health. 22 S409-463
[13]  
Allen N(2018)Is the EUnetHTA HTA Core Model® fit for purpose? Evaluation from an industry perspective Int. J. Technol. Assess. Health Care 34 458-606
[14]  
Liberti L(2013)A tutorial on sensitivity analyses in clinical trials: the what, why, when and how BMC Med. Res. Methodol. 13 92-undefined
[15]  
Walker SR(2019)PNS18 Shaping the future of European health technology assessments: Establishing a European PICO Value in Health. 22 S798-undefined
[16]  
Salek S(2018)Confirmatory versus explorative endpoint analysis: decision-making on the basis of evidence available from market authorization and early benefit assessment for oncology drugs Health Policy 122 599-undefined
[17]  
Chassagnol F(undefined)undefined undefined undefined undefined-undefined
[18]  
Marcelli G(undefined)undefined undefined undefined undefined-undefined
[19]  
Wagle J(undefined)undefined undefined undefined undefined-undefined
[20]  
Giuliani G(undefined)undefined undefined undefined undefined-undefined